LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Labcorp Holdings Inc (LH) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has strong financial growth and positive developments in its product offerings and partnerships, the technical indicators are bearish, hedge funds are selling, and there are no strong trading signals or recent congress trading data to support immediate action. It is better to monitor the stock for a more favorable entry point.
The technical indicators for LH are bearish. The MACD is negatively expanding, the RSI is neutral at 45.649, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 268.32, with key support at 260.634 and resistance at 276.006. The stock trend analysis predicts a 30% chance of a slight decline in the next day (-0.71%), week (-1.19%), and month (-3.01%).
Labcorp has launched the first FDA-cleared rapid fentanyl urine test in the U.S., which enhances its product portfolio and addresses a critical healthcare need. Additionally, its partnership with Children's Hospital of Philadelphia (CHOP) aims to drive innovation in pediatric diagnostics, which could strengthen its market position in healthcare services.
Hedge funds are selling the stock, with a 676.52% increase in selling activity over the last quarter. The technical indicators are bearish, and there is no recent congress trading data or strong trading signals to support a buy decision.
In Q3 2025, Labcorp demonstrated strong financial growth with an 8.58% YoY increase in revenue to $3.56 billion, a 54.22% YoY increase in net income to $261.1 million, and a 55.22% YoY increase in EPS to 3.12. Gross margin also improved by 4.68% to 26.82%.
Analysts have a positive outlook on Labcorp, with multiple firms raising price targets to $300 or higher. Evercore ISI, JPMorgan, and Baird maintain Outperform or Overweight ratings, highlighting the company's strong financial performance and its relative valuation discount compared to peers like Quest Diagnostics.
